*, Annals of the New York Academy of Sciences, vol.45, issue.3, pp.882-94, 1958. ,
DOI : 10.1111/j.1749-6632.1958.tb54906.x
Promotion of microtubule assembly in vitro by taxol, Nature, vol.446, issue.5698, pp.665-672, 1979. ,
DOI : 10.1083/jcb.71.3.749
Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia, Journal of the American Chemical Society, vol.93, issue.9, pp.2325-2332, 1971. ,
DOI : 10.1021/ja00738a045
Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: Findings from the EORTC 10001 randomized phase II trial, The Breast, vol.17, issue.2, pp.180-185, 2008. ,
DOI : 10.1016/j.breast.2007.09.002
Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8, Journal of Clinical Oncology, vol.18, issue.12, pp.2385-94, 2000. ,
DOI : 10.1200/JCO.2000.18.12.2385
Evolution of non-small cell lung cancer chemotherapy (Review), Oncology Reports, vol.13, pp.923-953, 2005. ,
DOI : 10.3892/or.13.5.923
Treatment of Advanced Non???Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel, Journal of Clinical Oncology, vol.23, issue.13, pp.3125-3162, 2005. ,
DOI : 10.1200/JCO.2005.00.224
Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies, Trends in Pharmacological Sciences, vol.29, issue.10, pp.515-524, 2008. ,
DOI : 10.1016/j.tips.2008.07.007
Progress in the development and acquisition of anticancer agents from marine sources, Annals of Oncology, vol.14, issue.11, pp.1607-1622, 2003. ,
DOI : 10.1093/annonc/mdg443
Total synthesis of taxol 11. de Lemos, E. et al. Total synthesis of discodermolide: optimization of the effective synthetic route, Nature Chemistry, vol.367, issue.14, pp.630-634, 1994. ,
Recent advances in the total synthesis of pharmaceutically relevant diterpenes, Natural Product Reports, vol.120, issue.2, pp.318-359, 2008. ,
DOI : 10.1039/b705652b
Total Synthesis of (???)-Laulimalide, Journal of the American Chemical Society, vol.124, issue.18, pp.4956-4963, 2002. ,
DOI : 10.1021/ja0258428
Direct observation of microtubule dynamics in living cells, Nature, vol.332, issue.6166, pp.724-730, 1988. ,
DOI : 10.1038/332724a0
Suppression of centromere dynamics by Taxol in living osteosarcoma cells, Cancer Res, vol.63, pp.2794-801, 2003. ,
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase, Molecular Cancer Therapeutics, vol.7, issue.7, pp.2003-2014, 2008. ,
DOI : 10.1158/1535-7163.MCT-08-0095
Antimitotic Peptides and Depsipeptides, Current Medicinal Chemistry-Anti-Cancer Agents, vol.2, issue.1, pp.19-53, 2002. ,
DOI : 10.2174/1568011023354263
Biochemistry of benzimidazole resistance, Acta Tropica, vol.56, issue.2-3, pp.245-62, 1994. ,
DOI : 10.1016/0001-706X(94)90066-3
Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane, Carcinogenesis, vol.29, issue.12, pp.2360-2368, 2008. ,
DOI : 10.1093/carcin/bgn241
Additivity of dilantin and vinblastine inhibitory effects on microtubule assembly, Cancer Res, vol.59, pp.4816-4838, 1999. ,
Microtubule Interactions with Chemically Diverse Stabilizing Agents: Thermodynamics of Binding to the Paclitaxel Site Predicts Cytotoxicity, Chemistry & Biology, vol.12, issue.12, pp.1269-79, 2005. ,
DOI : 10.1016/j.chembiol.2005.09.010
Synergistic Effects of Peloruside A and Laulimalide with Taxoid Site Drugs, but Not with Each Other, on Tubulin Assembly, Molecular Pharmacology, vol.70, issue.5, pp.1555-64, 2006. ,
DOI : 10.1124/mol.106.027847
A Unique Mode of Microtubule Stabilization Induced by Peloruside A, Journal of Molecular Biology, vol.378, issue.5, pp.1016-1046, 2008. ,
DOI : 10.1016/j.jmb.2008.03.026
How Do Microtubule-Targeted Drugs Work? An Overview, Current Cancer Drug Targets, vol.7, issue.8, pp.730-772, 2007. ,
DOI : 10.2174/156800907783220417
Targeting Microtubules for Cancer Chemotherapy, Current Medicinal Chemistry-Anti-Cancer Agents, vol.5, issue.1, pp.65-71, 2005. ,
DOI : 10.2174/1568011053352569
Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer, Clinical Breast Cancer, vol.9, issue.1, pp.23-31, 2009. ,
DOI : 10.3816/CBC.2009.n.004
Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non???Small-Cell Lung Cancer as Frontline and Second-Line Therapy, American Journal of Clinical Oncology, 2009. ,
DOI : 10.1097/COC.0b013e318199fb99
Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer., Journal of Clinical Oncology, vol.10, issue.11, pp.1754-61, 1992. ,
DOI : 10.1200/JCO.1992.10.11.1754
Combinations of pacliataxel and vinblastine and their effects on tublin polymerization and cellular cytotoxicity: Characterization of a synergistic schedule, vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines, pp.57-63, 1997. ,
DOI : 10.1002/(SICI)1097-0215(19980105)75:1<57::AID-IJC10>3.0.CO;2-A
Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations., Proceedings of the National Academy of Sciences, vol.90, issue.20, pp.9552-9558, 1993. ,
DOI : 10.1073/pnas.90.20.9552
Disrupting tumour blood vessels, Nature Reviews Cancer, vol.48, issue.8, pp.423-458, 2005. ,
DOI : 10.1038/sj.bjc.6690416
Vascular disrupting agents, Bioorganic & Medicinal Chemistry, vol.15, issue.2, pp.605-620, 2007. ,
DOI : 10.1016/j.bmc.2006.10.020
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature, Cancer Res, vol.57, pp.1829-1863, 1997. ,
Targeting tumour vasculature: the development of combretastatin A4, The Lancet Oncology, vol.2, issue.2, pp.82-89, 2001. ,
DOI : 10.1016/S1470-2045(00)00224-2
The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells, Blood, vol.99, issue.6, pp.2060-2069, 2002. ,
DOI : 10.1182/blood.V99.6.2060
Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability, Cancer Res, vol.61, pp.6413-6435, 2001. ,
Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer, Cancer Res, vol.62, pp.6864-6873, 2002. ,
Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics, British Journal of Cancer, vol.88, issue.11, pp.1793-1802, 2003. ,
DOI : 10.1038/sj.bjc.6600960
Is class III ??-tubulin a predictive factor in patients receiving tubulin-binding agents?, The Lancet Oncology, vol.9, issue.2, pp.168-75, 2008. ,
DOI : 10.1016/S1470-2045(08)70029-9
Ixabepilone: targeting ??III-tubulin expression in taxane-resistant malignancies, Molecular Cancer Therapeutics, vol.8, issue.1, pp.17-25, 2009. ,
DOI : 10.1158/1535-7163.MCT-08-0986
Molecular Basis for Class V ??-Tubulin Effects on Microtubule Assembly and Paclitaxel Resistance, Journal of Biological Chemistry, vol.284, issue.19, pp.13023-13055, 2009. ,
DOI : 10.1074/jbc.M900167200
Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance, J Biol Chem, vol.270, pp.31269-75, 1995. ,
Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol 63. Kavallaris, M. et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells, Br J Cancer Cancer Res, vol.80, issue.61, pp.1020-1025, 1999. ,
Class III ??-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non Small Cell Lung Cancer, Cancer Research, vol.67, issue.19, pp.9356-63, 2007. ,
DOI : 10.1158/0008-5472.CAN-07-0509
??III-Tubulin Is a Multifunctional Protein Involved in Drug Sensitivity and Tumorigenesis in Non-Small Cell Lung Cancer, Cancer Research, vol.70, issue.12, pp.4995-5003, 2010. ,
DOI : 10.1158/0008-5472.CAN-09-4487
Class III ??-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients, Clinical Cancer Research, vol.12, issue.9, pp.2774-2783, 2006. ,
DOI : 10.1158/1078-0432.CCR-05-2715
Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant ??-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization, Journal of Biological Chemistry, vol.272, issue.27, pp.17118-17143, 1997. ,
DOI : 10.1074/jbc.272.27.17118
??-Tubulin Mutations Are Associated with Resistance to 2-Methoxyestradiol in MDA-MB-435 Cancer Cells, Cancer Research, vol.65, issue.20, pp.9406-9420, 2005. ,
DOI : 10.1158/0008-5472.CAN-05-0088
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of ??-tubulin (Asp26Glu) and less stable microtubules, Molecular Cancer Therapeutics, vol.5, issue.2, pp.270-278, 2006. ,
DOI : 10.1158/1535-7163.MCT-05-0190
Paclitaxel Resistance in Non???Small-Cell Lung Cancer Associated With Beta-Tubulin Gene Mutations, Journal of Clinical Oncology, vol.17, issue.6, pp.1786-93, 1999. ,
DOI : 10.1200/JCO.1999.17.6.1786
Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers, Mol Cancer Ther, vol.1, pp.215-240, 2002. ,
Re: Genetic Analysis of the beta-Tubulin Gene, TUBB, in Non-Small-Cell Lung Cancer, CancerSpectrum Knowledge Environment, vol.94, issue.10, pp.776-783, 2002. ,
DOI : 10.1093/jnci/94.10.776
Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis, Nature Medicine, vol.48, issue.1, pp.72-81, 1996. ,
DOI : 10.1038/nm0196-72
These data suggested that paclitaxel could be more active in cells which had lost normal P53 function, a common occurrence in tumor cells. 74 Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment, Clin Cancer Res, vol.4, pp.1047-54, 1998. ,
p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel, Cancer Res, vol.57, pp.870-874, 1997. ,
p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma, Cancer, vol.18, issue.4, pp.769-73, 2000. ,
DOI : 10.1002/1097-0142(20000815)89:4<769::AID-CNCR8>3.0.CO;2-6
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy, Annals of Oncology, vol.17, issue.10, pp.1504-1515, 2006. ,
DOI : 10.1093/annonc/mdl147
A Small-Molecule Inhibitor of Bcl-XL Potentiates the Activity of Cytotoxic Drugs In vitro and In vivo, Cancer Research, vol.66, issue.17, pp.8731-8740, 2006. ,
DOI : 10.1158/0008-5472.CAN-06-0367
Human GTSE-1 Regulates p21CIP1/WAF1 Stability Conferring Resistance to Paclitaxel Treatment, Journal of Biological Chemistry, vol.285, issue.8, pp.5274-81, 2010. ,
DOI : 10.1074/jbc.M109.045948
Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells, Proceedings of the National Academy of Sciences, vol.107, issue.6, pp.2503-2511 ,
DOI : 10.1073/pnas.0910649107
Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1??, Journal of Cancer Research and Clinical Oncology, vol.89, issue.3, pp.447-56 ,
DOI : 10.1007/s00432-009-0675-4
Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation, Clinical Cancer Research, vol.16, issue.2, pp.681-90, 2010. ,
DOI : 10.1158/1078-0432.CCR-09-1091
The role of glutathione-S-transferase in anti-cancer drug resistance, Oncogene, vol.22, issue.47, pp.7369-75, 2003. ,
DOI : 10.1038/sj.onc.1206940
MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression, Journal of Biological Chemistry, vol.285, issue.28, pp.21496-507, 2010. ,
DOI : 10.1074/jbc.M109.083337
MiR-148a Attenuates Paclitaxel Resistance of Hormone-refractory, Drug-resistant Prostate Cancer PC3 Cells by Regulating MSK1 Expression, Journal of Biological Chemistry, vol.285, issue.25, pp.19076-84, 2010. ,
DOI : 10.1074/jbc.M109.079525
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract, Journal of Clinical Oncology, vol.27, issue.27, pp.4454-61, 2009. ,
DOI : 10.1200/JCO.2008.20.5534
Structural insight into the inhibition of tubulin by vinca domain peptide ligands, EMBO reports, vol.35, issue.11, pp.1101-1107, 2008. ,
DOI : 10.1107/S0907444900014736
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer, Cancer Chemotherapy and Pharmacology, vol.21, issue.Suppl 2, pp.173-80, 2008. ,
DOI : 10.1007/s00280-007-0665-7
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses, Cancer Chemotherapy and Pharmacology, vol.5, issue.2, pp.285-93, 2007. ,
DOI : 10.1007/s00280-006-0382-7
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma, Journal of Clinical Oncology, vol.27, issue.32, pp.5410-5417, 2009. ,
DOI : 10.1200/JCO.2008.21.6150
A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane., Journal of Clinical Oncology, vol.28, issue.18_suppl, pp.7-1004, 2010. ,
DOI : 10.1200/jco.2010.28.18_suppl.cra1004
A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results. -ASCO, J Clin Oncol, vol.27, p.1053, 2009. ,
MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo, Mol Cancer Ther, vol.2, pp.873-84, 2003. ,
Alternative formulations of paclitaxel, Cancer Treatment Reviews, vol.23, issue.2, pp.87-95, 1997. ,
DOI : 10.1016/S0305-7372(97)90022-0
Cremophor EL, European Journal of Cancer, vol.37, issue.13, pp.1590-1598, 2001. ,
DOI : 10.1016/S0959-8049(01)00171-X
-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer, Journal of Clinical Oncology, vol.27, issue.22, pp.3611-3620, 2009. ,
DOI : 10.1200/JCO.2008.18.5397
Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy, The Journal of Urology, vol.181, issue.4, pp.1672-1679, 2009. ,
DOI : 10.1016/j.juro.2008.11.121
Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane??) on three treatment schedules in patients with solid tumors, Cancer Chemotherapy and Pharmacology, vol.20, issue.5, pp.759-66, 2007. ,
DOI : 10.1007/s00280-007-0423-x
Phase II Evaluation of Nanoparticle Albumin???Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer, Journal of Clinical Oncology, vol.27, issue.9, pp.1426-1457, 2009. ,
DOI : 10.1200/JCO.2008.18.9548
Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies, Clinical Cancer Research, vol.10, issue.11, pp.3708-3724, 2004. ,
DOI : 10.1158/1078-0432.CCR-03-0655
Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel, Proceedings of the National Academy of Sciences, vol.95, issue.26, pp.15798-802, 1998. ,
DOI : 10.1073/pnas.95.26.15798
Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study, Journal of Clinical Oncology, vol.28, issue.1, pp.149-53, 2010. ,
DOI : 10.1200/JCO.2009.24.1455
Development of Novel Chemotherapeutic Agents to Evade the Mechanisms of Multidrug Resistance (MDR), Seminars in Oncology, vol.32, pp.22-28, 2005. ,
DOI : 10.1053/j.seminoncol.2005.09.013
Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases, Neuro-Oncology, vol.11, issue.2, pp.158-66, 2009. ,
DOI : 10.1215/15228517-2008-072
Activity of Epothilone B Analogues Ixabepilone and Patupilone in Hormone-Refractory Prostate Cancer, Clinical Prostate Cancer, vol.3, issue.2, pp.80-82, 2004. ,
DOI : 10.1016/S1540-0352(11)70066-X
Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial, British Journal of Cancer, vol.8, issue.8, pp.1241-1248, 2009. ,
DOI : 10.1002/cncr.20977
Sagopilone, a microtubule stabilizer for the potential treatment of cancer, Curr Opin Investig Drugs, vol.10, pp.1359-71, 2009. ,
Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas, Journal of Neuro-Oncology, vol.45, issue.2, pp.61-65, 2009. ,
DOI : 10.1007/s11060-009-9890-8
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel, Investigational New Drugs, vol.22, issue.14S, pp.565-70, 2007. ,
DOI : 10.1007/s10637-007-9068-1
Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results, Journal of Clinical Oncology, vol.21, issue.15, pp.2815-2837, 2003. ,
DOI : 10.1200/JCO.2003.05.185
Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood Flow, Journal of Clinical Oncology, vol.21, issue.23, pp.4428-4466, 2003. ,
DOI : 10.1200/JCO.2003.12.986
Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer, Clinical Cancer Research, vol.10, issue.1, pp.96-100, 2004. ,
DOI : 10.1158/1078-0432.CCR-0364-3
A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome, Thyroid, vol.19, issue.3, pp.233-273, 2009. ,
DOI : 10.1089/thy.2008.0321
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors, Investigational New Drugs, vol.77, issue.2, pp.159-67, 2008. ,
DOI : 10.1007/s10637-008-9112-9
Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate, Anticancer Res, vol.23, pp.1433-1473, 2003. ,
AVE8062: a new combretastatin derivative vascular disrupting agent, Expert Opinion on Investigational Drugs, vol.22, issue.10, pp.1541-1549, 2009. ,
DOI : 10.1007/s10637-008-9112-9
Initial results of a first-in-man phase I study of EPC2407, a novel small molecule microtubule inhibitor anticancer agent with tumor vascular endothelial disrupting activity, Journal of Clinical Oncology, vol.26, issue.15_suppl, p.2531, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.2531
Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models, International Journal of Oncology, vol.31, pp.353-60, 2007. ,
DOI : 10.3892/ijo.31.2.353
A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer, Annals of Oncology, vol.21, issue.2, pp.305-316, 2010. ,
DOI : 10.1093/annonc/mdp311
A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer, Clinical Cancer Research, vol.11, issue.18, pp.6625-6658, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-0440
Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer, Investigational New Drugs, vol.57, issue.1, pp.41-49, 2007. ,
DOI : 10.1007/s10637-006-9008-5
Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma, Clinical Cancer Research, vol.13, issue.20, pp.6162-6169, 2007. ,
DOI : 10.1158/1078-0432.CCR-07-0807
Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies, Clinical Cancer Research, vol.15, issue.4, pp.1460-1465, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-1599
The hematopoietic-specific ??1-tubulin is naturally resistant to 2-Methoxyestradiol and protects patients from drug-induced myelosuppression, Cell Cycle, vol.8, issue.23, pp.3914-3938, 2009. ,
DOI : 10.4161/cc.8.23.10105
Cevipabulin (TTI-237): Preclinical and clinical results for a novel antimicrotubule agent, Methods and Findings in Experimental and Clinical Pharmacology, vol.31, issue.7, pp.443-450, 2009. ,
DOI : 10.1358/mf.2009.31.7.1415893
Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth, Clinical Cancer Research, vol.10, issue.15, pp.5187-201, 2004. ,
DOI : 10.1158/1078-0432.CCR-04-0360
Synergistic Suppression of Microtubule Dynamics by Discodermolide and Paclitaxel in Non-Small Cell Lung Carcinoma Cells, Cancer Research, vol.64, issue.14, pp.4957-64, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-0693
Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines, Clin Cancer Res, vol.6, pp.1978-87, 2000. ,
Total synthesis and biological evaluation of potent analogues of dictyostatin: Modification of the C2???C6 dienoate region, Bioorganic & Medicinal Chemistry Letters, vol.18, issue.23, pp.6268-72, 2008. ,
DOI : 10.1016/j.bmcl.2008.09.109
A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer, International Journal of Gynecological Cancer, vol.16, issue.1, pp.71-77, 2006. ,
DOI : 10.1111/j.1525-1438.2006.00276.x
Phase 2 study of cryptophycin 52 ( LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer, Lung Cancer, vol.39, issue.2, pp.197-206, 2003. ,
DOI : 10.1016/S0169-5002(02)00511-1
Tubulin: A Target for Antineoplastic Drugs into the Cancer Cells but also in the Peripheral Nervous System, Current Medicinal Chemistry, vol.16, issue.11, pp.1315-1339, 2009. ,
DOI : 10.2174/092986709787846488
Peripheral nerve damage associated with administration of taxanes in patients with cancer, Critical Reviews in Oncology/Hematology, vol.66, issue.3, pp.218-246, 2008. ,
DOI : 10.1016/j.critrevonc.2008.01.008
Neurotoxicity of taxanes: Symptoms and quality of life assessment, Breast Cancer, vol.36, issue.1, pp.92-101, 2004. ,
DOI : 10.1007/BF02968010
Changes in Neurologic Function Tests May Predict Neurotoxicity Caused by Ixabepilone, Journal of Clinical Oncology, vol.24, issue.13, pp.2084-91, 2006. ,
DOI : 10.1200/JCO.2005.04.2820
Biochemical parameters in the diagnosis and monitoring of neurotoxicity of antitumor cytostatics, Bull Exp Biol Med, vol.132, pp.1093-1098, 2001. ,
Evaluation of long-term toxicity after chemotherapy for testicular cancer., Journal of Clinical Oncology, vol.14, issue.11, pp.2923-2955, 1996. ,
DOI : 10.1200/JCO.1996.14.11.2923
Neurological adverse effects caused by cytotoxic and targeted therapies, Nature Reviews Clinical Oncology, vol.141, issue.10, pp.596-603, 2009. ,
DOI : 10.1038/nrclinonc.2009.128
Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition, Cell Cycle, vol.7, issue.7, pp.940-949, 2008. ,
DOI : 10.4161/cc.7.7.5625
A Neuronal and Astrocyte Co-Culture Assay for High Content Analysis of Neurotoxicity, Journal of Visualized Experiments, vol.27, issue.27, pp.10-3791, 2009. ,
DOI : 10.3791/1173
Animal models of chemotherapy-evoked painful peripheral neuropathies, Neurotherapeutics, vol.58, issue.4, pp.620-629, 2009. ,
DOI : 10.1016/j.nurt.2009.07.003
Comparative neurotoxicity of tubulin-binding drugs: Inhibition of goldfish optic nerve regeneration, Toxicology and Applied Pharmacology, vol.80, issue.2, pp.308-323, 1985. ,
DOI : 10.1016/0041-008X(85)90088-2
Gene expression changes in developing zebrafish as potential markers for rapid developmental neurotoxicity screening, Neurotoxicology and Teratology, vol.32, issue.1, 2009. ,
DOI : 10.1016/j.ntt.2009.04.065
In vivo modulation of vincristine-induced neurotoxicity in Lymnaea stagnalis, by the ACTH(4?9)analogue Org 2766, Journal of Neuro-Oncology, vol.30, issue.3, pp.173-80, 1996. ,
DOI : 10.1007/BF00177268
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane, Journal of Clinical Oncology, vol.27, issue.18, pp.2954-61, 2009. ,
DOI : 10.1200/JCO.2008.17.7618
URL : https://hal.archives-ouvertes.fr/hal-01440451
Indibulin, a Novel Microtubule Inhibitor, Discriminates between Mature Neuronal and Nonneuronal Tubulin, Cancer Research, vol.69, issue.1, pp.171-178, 2009. ,
DOI : 10.1158/0008-5472.CAN-08-1342
Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors, Investigational New Drugs, vol.95, issue.2, pp.163-70, 2010. ,
DOI : 10.1007/s10637-009-9244-6
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours, British Journal of Cancer, vol.24, issue.5, pp.894-903, 2008. ,
DOI : 10.1016/S1471-4892(01)00064-9
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck, Investigational New Drugs, vol.54, issue.3, pp.257-64, 2008. ,
DOI : 10.1007/s10637-007-9098-8
A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168), Investigational New Drugs, vol.43, issue.3, pp.265-72, 2008. ,
DOI : 10.1007/s10637-007-9103-2
A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse, Investigational New Drugs, vol.2, issue.3, pp.231-235, 1992. ,
DOI : 10.1007/BF00877252
Antirestenotic Effects of a Novel Polymer-Coated D-24851 Eluting Stent. Experimental Data in a Rabbit Iliac Artery Model, CardioVascular and Interventional Radiology, vol.104, issue.4, pp.1192-200, 2007. ,
DOI : 10.1007/s00270-007-9027-4
Phase I Study of the Novel Epothilone Analog Ixabepilone (BMS-247550) in Patients With Advanced Solid Tumors and Lymphomas, Journal of Clinical Oncology, vol.25, issue.9, pp.1082-1090, 2007. ,
DOI : 10.1200/JCO.2006.08.7304
Phase I and pharmacokinetic study of rhizoxin, Cancer Res, vol.52, pp.2894-2902, 1992. ,
Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors, Clinical Cancer Research, vol.11, issue.21, pp.7825-7858, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-0058
Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer, Journal of Thoracic Oncology, vol.3, issue.8, pp.894-901, 2008. ,
DOI : 10.1097/JTO.0b013e31817e6669
Epothilones in the treatment of cancer, Expert Opinion on Investigational Drugs, vol.5, issue.6, pp.691-702, 2006. ,
DOI : 10.1158/1078-0432.CCR-04-2019
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours, Annals of Oncology, vol.17, issue.8, pp.1313-1322, 2006. ,
DOI : 10.1093/annonc/mdl097
Managing taxane toxicities, Support Care Cancer, vol.11, pp.144-151, 2003. ,
Chromosomal instability determines taxane response, Proceedings of the National Academy of Sciences, vol.106, issue.21, pp.8671-8677, 2009. ,
DOI : 10.1073/pnas.0811835106
Paclitaxel resistance in untransformed human mammary epithelial cells is associated with an aneuploidy-prone phenotype, British Journal of Cancer, vol.350, issue.9, pp.1218-1242, 2007. ,
DOI : 10.1016/j.ccr.2006.12.003
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration, Mutation Research/Genetic Toxicology and Environmental Mutagenesis, vol.583, issue.2, pp.105-124, 2005. ,
DOI : 10.1016/j.mrgentox.2005.01.013
The Coral-Derived Natural Products Eleutherobin and Sarcodictyins A and B:?? Effects on the Assembly of Purified Tubulin with and without Microtubule-Associated Proteins and Binding at the Polymer Taxoid Site, Biochemistry, vol.38, issue.17, pp.5490-5498, 1999. ,
DOI : 10.1021/bi983023n
Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents, Cancer Res, vol.59, pp.653-60, 1999. ,
Laulimalide and Paclitaxel: A Comparison of Their Effects on Tubulin Assembly and Their Synergistic Action When Present Simultaneously, Molecular Pharmacology, vol.66, issue.1, pp.113-134, 2004. ,
DOI : 10.1124/mol.66.1.113
Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin, Mol Cancer Ther, vol.3, pp.1319-1346, 2004. ,
Peloruside A Does Not Bind to the Taxoid Site on ??-Tubulin and Retains Its Activity in Multidrug-Resistant Cell Lines, Cancer Research, vol.64, issue.15, pp.5063-5070, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-0771
The Taccalonolides: Microtubule Stabilizers That Circumvent Clinically Relevant Taxane Resistance Mechanisms, Cancer Research, vol.68, issue.21, pp.8881-8889, 2008. ,
DOI : 10.1158/0008-5472.CAN-08-2037
Synthesis and Biological Evaluation of 4-Arylcoumarin Analogues of Combretastatins, Journal of Medicinal Chemistry, vol.46, issue.25, pp.5437-5481, 2003. ,
DOI : 10.1021/jm030903d
Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites, Nature Chemical Biology, vol.78, issue.2, pp.117-142, 2007. ,
DOI : 10.1038/nchembio853
Molecular Mechanisms of Patupilone Resistance, Cancer Research, vol.68, issue.24, pp.10197-204, 2008. ,
DOI : 10.1158/0008-5472.CAN-08-2091
532 The seco-taxane idn5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance, European Journal of Cancer Supplements, vol.2, issue.8, pp.2397-405, 2005. ,
DOI : 10.1016/S1359-6349(04)80540-8
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate, Cancer Research, vol.68, issue.22, pp.9280-90, 2008. ,
DOI : 10.1158/0008-5472.CAN-08-1776
Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma, Clinical Cancer Research, vol.15, issue.12, pp.4038-4083, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-2808
A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC), Journal of Clinical Oncology, vol.25, p.1042, 2007. ,
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer, Journal of Clinical Oncology, vol.28, issue.16, pp.2698-704 ,
DOI : 10.1200/JCO.2009.26.2071
Technology evaluation: huN901-DM1, ImmunoGen, Curr Opin Mol Ther, vol.7, pp.394-401, 2005. ,
Microtubules as a target for anticancer drugs, Nature Reviews Cancer, vol.4, issue.4, pp.253-65, 2004. ,
DOI : 10.1038/nrc1317
Phase I multicenter study to assess the safety, tolerability, and pharmacokinetics of AZD4877 administered twice weekly in adult patients with advanced solid malignancies, Journal of Clinical Oncology, vol.26, issue.15_suppl, p.2516, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.2516
Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial, Journal of Clinical Oncology, vol.27, issue.26, pp.4287-92, 2009. ,
DOI : 10.1200/JCO.2008.21.6887
The case for survivin as a regulator of microtubule dynamics and cell-death decisions, Current Opinion in Cell Biology, vol.18, issue.6, pp.609-624, 2006. ,
DOI : 10.1016/j.ceb.2006.08.015
Catalysis of the microtubule on-rate is the major parameter regulating the depolymerase activity of MCAK, Nature Structural & Molecular Biology, vol.196, issue.1, pp.77-82, 2010. ,
DOI : 10.1038/45483
Stathmin 1: a novel therapeutic target for anticancer activity, Expert Review of Anticancer Therapy, vol.8, issue.9, pp.1461-70, 2008. ,
DOI : 10.1586/14737140.8.9.1461
Markers predicting clinical benefit in breast cancer from microtubuletargeting agents, Ann Oncol, vol.18, issue.12, pp.15-20, 2007. ,
Chemoresistance in Non-Small Cell Lung Cancer, Current Medicinal Chemistry-Anti-Cancer Agents, vol.5, issue.1, pp.73-88, 2005. ,
DOI : 10.2174/1568011053352604
Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer, Journal of Clinical Oncology, vol.25, issue.29, pp.4528-4563, 2007. ,
DOI : 10.1200/JCO.2006.10.4752
Characterization of the azidopine and vinblastine binding site of P-glycoprotein, J Biol Chem, vol.267, pp.21020-21026, 1992. ,
Beketic-Oreskovic, L. & Sikic, B. I. MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES- SA cells, British Journal of Cancer, vol.83, issue.7, pp.892-900, 2000. ,
DOI : 10.1054/bjoc.2000.1371
Pharmacological characterization of multidrug resistant MRPtransfected human tumor cells, Cancer Res, vol.54, pp.5902-5912, 1994. ,
Biochemical genetic analysis of indanocine resistance in human leukemia, Cancer Res, vol.61, pp.7248-54, 2001. ,
In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines, Cancer Chemotherapy and Pharmacology, vol.43, issue.2, pp.115-140, 1999. ,
DOI : 10.1007/s002800050871
Role of P-glycoprotein in dolastatin 10 resistance, Biochemical Pharmacology, vol.48, issue.3, pp.609-621, 1994. ,
DOI : 10.1016/0006-2952(94)90292-5
Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones, Proceedings of the National Academy of Sciences, vol.105, issue.35, pp.13157-62, 2008. ,
DOI : 10.1073/pnas.0804773105
Efflux of Depsipeptide FK228 (FR901228, NSC-630176) Is Mediated by P-Glycoprotein and Multidrug Resistance-Associated Protein 1, Journal of Pharmacology and Experimental Therapeutics, vol.313, issue.1, pp.268-76, 2005. ,
DOI : 10.1124/jpet.104.072033
Making Epothilones Fluoresce: Design, Synthesis, and Biological Characterization of a Fluorescent N12-Aza-Epothilone (Azathilone), ChemBioChem, vol.46, issue.15, pp.2513-2534, 2009. ,
DOI : 10.1002/cbic.200900376
The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo, British Journal of Cancer, vol.77, issue.10, pp.1532-1541, 2007. ,
DOI : 10.1111/j.1349-7006.2006.00330.x
Heterocyclic and Phenyl Double-Bond-Locked Combretastatin Analogues Possessing Potent Apoptosis-Inducing Activity in HL60 and in MDR Cell Lines, Journal of Medicinal Chemistry, vol.48, issue.3, pp.723-759, 2005. ,
DOI : 10.1021/jm049622b
Gateways to clinical trials, Methods Find Exp Clin Pharmacol, vol.30, pp.67-99, 2008. ,
Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression, Anticancer Res, vol.25, pp.3865-70, 2005. ,
Antineoplastic activity of 2-methoxyestradiol in human pancreatic and gastric cancer cells with different multidrug-resistant phenotypes, Journal of Gastroenterology and Hepatology, vol.65, issue.9, pp.1469-73, 2007. ,
DOI : 10.1158/0008-5472.CAN-05-0088
Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors, Cancer Chemotherapy and Pharmacology, vol.9, issue.Suppl 2, pp.203-212, 2007. ,
DOI : 10.1007/s00280-006-0362-y
A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer, Cancer Chemotherapy and Pharmacology, vol.24, issue.3, pp.453-461, 2008. ,
DOI : 10.1007/s00280-007-0489-5
Phase I study of larotaxel administered as a 1-h intravenous infusion every 3??weeks to Japanese patients with advanced solid tumours, Cancer Chemotherapy and Pharmacology, vol.42, issue.Suppl 5, pp.129-165, 2009. ,
DOI : 10.1007/s00280-009-1014-9
Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy, Annals of Oncology, vol.19, issue.7 ,
DOI : 10.1093/annonc/mdn060
Larotaxel: broadening the road with new taxanes, Expert Opinion on Investigational Drugs, vol.18, issue.8, pp.1183-1192, 2009. ,
DOI : 10.1080/02841860500486630
Phase II study of ortataxel in taxane-resistant breast cancer, Journal of Clinical Oncology, vol.26, issue.15_suppl, p.1066, 2008. ,
DOI : 10.1200/jco.2008.26.15_suppl.1066
Phase II trial of DJ-927 as a second-line treatment for colorectal cancer demonstrates objective responses, Journal of Clinical Oncology, vol.23, issue.16_suppl, p.3654, 2005. ,
DOI : 10.1200/jco.2005.23.16_suppl.3654
Phase I/II Study of a 3 Weekly Oral Taxane (DJ-927) in Patients with Recurrent, Advanced Non-small Cell Lung Cancer, Journal of Thoracic Oncology, vol.3, issue.7, pp.745-50, 2008. ,
DOI : 10.1097/JTO.0b013e31817c73ff
Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas, Investigational New Drugs, vol.16, issue.1, pp.87-92, 1998. ,
DOI : 10.1023/A:1006078930550
Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity ,
Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85--a synthetic agent binding at the colchicine site designed to overcome multidrug resistance, British Journal of Cancer, vol.75, issue.4, pp.608-621, 1997. ,
DOI : 10.1038/bjc.1997.107
Phase I study of E7010, Cancer Chemotherapy and Pharmacology, vol.42, issue.2, pp.127-161, 1998. ,
DOI : 10.1007/s002800050795
Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors, Investigational New Drugs, vol.1, issue.3, pp.227-262, 2007. ,
DOI : 10.1007/s10637-006-9027-2